Market Overview

UPDATE: Credit Suisse Downgrades St. Jude Medical to Neutral, Lowers PT

Related STJ
Abbott Labs Has 'An Emerging Picture Of Top-Tier Growth,' Says Morgan Stanley
Dept. of Homeland Security Provides A Timely Update On Abbott, St. Jude

In a report published Friday, Credit Suisse downgraded its rating on St. Jude Medical (NYSE: STJ) from Outperform to Neutral, and lowered its price target from $45.00 to $43.00.

Credit Suisse noted, “Our downgrade is driven by the RESPECT result and the recent FDA form 483 that could result in a Warning Letter for the CRM division. While we believe that DURATA will be exonerated, beginning with the independent analysis in next month's Product Performance Report, perceived regulatory risk and skepticism regarding the pipeline (given STJ's misplaced focus of the investor base on the trial) will likely offset fading Durata concerns. Upside risk could stem from an optically improving ICD market (due to the lapping of destocking) and/or resurrection of CardioMEMS. There are no changes to our estimates (which did not include any PFO numbers).”

St. Jude Medical closed on Thursday at $38.27.

Latest Ratings for STJ

Jul 2016WedbushDowngradesOutperformNeutral
Jul 2016Leerink SwannDowngradesOutperformMarket Perform
May 2016BarclaysDowngradesOverweightEqual-Weight

View More Analyst Ratings for STJ
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Downgrades Analyst Ratings


Related Articles (STJ)

View Comments and Join the Discussion!